NCT02771340View on ClinicalTrials.gov

Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Uveal MelanomaChoroid Neoplasm
Interventions
BIOLOGICAL

ICON-1

Intravitreal injection of ICON-1

Trial Locations (8)

19107

Philadelphia

48073

Royal Oak

49546

Grand Rapids

66211

Leawood

80401

Denver

94109

San Francisco

97239

Portland

02114

Boston

Sponsors
All Listed Sponsors
lead

Iconic Therapeutics, Inc.

INDUSTRY

NCT02771340 - Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma | Biotech Hunter | Biotech Hunter